Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are REPL, EWTX, ABVX, SLNO, CMPS, and represent 49.50% of Ally Bridge Group's stock portfolio.
- Added to shares of these 7 stocks: EWTX (+$11M), ABVX (+$9.4M), IVA (+$7.0M), NERV (+$6.7M), QURE, OVID, PMN.
- Started 7 new stock positions in EWTX, ABVX, IVA, QURE, PMN, OVID, NERV.
- Reduced shares in these 10 stocks: PRAX (-$24M), REPL (-$23M), SLNO (-$18M), MDGL (-$15M), ASND (-$10M), LENZ (-$8.2M), CMPS (-$7.4M), AMLX (-$5.9M), MNPR (-$5.3M), TSHA (-$5.2M).
- Sold out of its positions in ATYR, AMLX, ARQT, ASND, AVTX, LENZ, MDGL, MNMD, MNPR, MLTX. ProMIS Neurosciences, TARS, TECX.
- Ally Bridge Group was a net seller of stock by $-106M.
- Ally Bridge Group has $96M in assets under management (AUM), dropping by -41.55%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 16 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Replimune Group Call Option (REPL) | 12.2 | $12M | -66% | 1.2M | 9.72 |
|
| Edgewise Therapeutics (EWTX) | 11.5 | $11M | NEW | 445k | 24.82 |
|
| Abivax Sa Sponsored Ads (ABVX) | 9.8 | $9.4M | NEW | 70k | 134.85 |
|
| Soleno Therapeutics (SLNO) | 8.1 | $7.8M | -69% | 168k | 46.30 |
|
| Compass Pathways Sponsored Ads Call Option (CMPS) | 7.9 | $7.6M | -49% | 1.1M | 6.90 |
|
| Atai Beckley Nv SHS | 7.3 | $7.0M | -25% | 1.7M | 4.09 |
|
| Inventiva Sa Ads (IVA) | 7.3 | $7.0M | NEW | 1.5M | 4.65 |
|
| Minerva Neurosciences Com New (NERV) | 6.9 | $6.7M | NEW | 1.7M | 4.02 |
|
| Praxis Precision Medicines I Com New (PRAX) | 6.1 | $5.9M | -80% | 20k | 294.74 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 5.5 | $5.3M | -49% | 957k | 5.50 |
|
| Uniqure Nv SHS Call Option (QURE) | 5.0 | $4.8M | NEW | 200k | 23.93 |
|
| Eupraxia Pharmaceuticals (EPRX) | 3.1 | $3.0M | -56% | 398k | 7.55 |
|
| Ovid Therapeutics (OVID) | 3.0 | $2.9M | NEW | 1.8M | 1.63 |
|
| Solid Biosciences Com New (SLDB) | 2.4 | $2.3M | -24% | 414k | 5.64 |
|
| Aadi Bioscience (WHWK) | 2.1 | $2.0M | 818k | 2.42 |
|
|
| Promis Neurosciences Com Shs (PMN) | 1.8 | $1.7M | NEW | 249k | 6.83 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2025 Q4 filed Feb. 17, 2026
- Ally Bridge Group 2025 Q3 filed Nov. 14, 2025
- Ally Bridge Group 2025 Q2 filed Aug. 14, 2025
- Ally Bridge Group 2025 Q1 filed May 15, 2025
- Ally Bridge Group 2024 Q4 filed Feb. 14, 2025
- Ally Bridge Group 2024 Q3 filed Nov. 14, 2024
- Ally Bridge Group 2024 Q2 filed Aug. 14, 2024
- Ally Bridge Group 2024 Q1 filed May 15, 2024
- Ally Bridge Group 2023 Q4 filed Feb. 14, 2024
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022
- Ally Bridge Group 2022 Q2 filed Aug. 15, 2022
- Ally Bridge Group 2022 Q1 filed May 16, 2022